0
Letters |

Postmenopausal Hormone Replacement, Body Mass Index, and Quality of Life

Carmen Rodriguez, MD, MPH; Eugenia E. Calle, PhD
[+] Author Affiliations

Stephen J. Lurie, MD, PhDSenior Editor: IndividualAuthor

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

More Author Information
JAMA. 2002;287(17):2210-2211. doi:10-1001/pubs.JAMA-ISSN-0098-7484-287-17-jlt0501
Text Size: A A A
Published online

To the Editor: Dr Hlatky and colleagues1 reported that postmenopausal hormone therapy improved quality of life only among women who reported flushing at baseline. We suspect that the women in this study who reported flushing were generally thinner than those who did not; thus, we suggest that the results should be reported stratified by body mass index (BMI). Menopausal symptoms, including flushing, are related to the dramatic decrease of estrogen levels due to depletion of ovarian function. After menopause, peripheral aromatization of androgens in adipose tissue is the primary source of endogenous estrogen, and circulating levels of estrogen in postmenopausal women increase with increasing body mass.2 Significantly lower levels of estradiol and estrone are found in women with frequent hot flashes,2 and flushing is more likely among thin women.2

Several observational studies have suggested that both risks and benefits of hormone therapy are observed only in thin women.3 4 Breast cancer rates are generally lower among thin postmenopausal women and increase with hormone therapy, while there appears to be no such increase among women with higher BMI.3 Similarly, we have reported that the inverse association between hormone use and coronary heart disease was strongest for thin women.4 These results suggest that there may be a threshold level of estrogen beyond which additional exogenous estrogen has negligible effects.

Women included in the HERS trial, upon which Hlatky et al based their analysis, have higher BMI than average US women; 57% of the women in the treatment group5 had a BMI of greater than 27 kg/m2 compared with 43% of US women in the same age group.6 If there is indeed a threshold in the level of biologically important doses of estrogens, an improvement in mental health and depression associated with hormone use among women in the HERS trial would only be expected in thinner women.

REFERENCES

Hlatky  MA, Boothroyd  D, Vittinghoff  E, Sharp  P, Whooley  MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA. 2002;287:591-597.
Erlik  Y, Meldrum  D, Judd  H. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol. 1982;59:403-407.
Collaborative Group on Hormonal Factors in Breast Cancer,  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
Rodriguez  C, Calle  E, Patel  A, Tatham  L, Jacobs  E, Thun  M. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol. 2001;153:145-152.
Hulley  S, Grady  D, Bush  T.  et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group,  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
Kuczmarski  R, Carroll  M, Flegal  K, Troinano  R. Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988 to 1994). Obesity Res. 1997;5:542-548.

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Hlatky  MA, Boothroyd  D, Vittinghoff  E, Sharp  P, Whooley  MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA. 2002;287:591-597.
Erlik  Y, Meldrum  D, Judd  H. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol. 1982;59:403-407.
Collaborative Group on Hormonal Factors in Breast Cancer,  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
Rodriguez  C, Calle  E, Patel  A, Tatham  L, Jacobs  E, Thun  M. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol. 2001;153:145-152.
Hulley  S, Grady  D, Bush  T.  et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group,  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
Kuczmarski  R, Carroll  M, Flegal  K, Troinano  R. Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988 to 1994). Obesity Res. 1997;5:542-548.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.